Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM

被引：0

作者：

Harrison, Stephen A. ^{[1
]}

Neff, Guy ^{[2
]}

Gunn, Nadege ^{[3
]}

Flyer, Abigail ^{[4
]}

MacConell, Leigh ^{[5
]}

机构：

[1] Pinnacle Clin Res, San Antonio, TX USA

[2] Covenant Metab Specialists, Sarasota, FL USA

[3] Impact Res Inst, Waco, TX USA

[4] Pacific Northwest Stat Consulting, Woodinville, WA USA

[5] HighTide Therapeut, Rockville, MD USA

来源：

JOURNAL OF HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT-227

引用

页码：S614 / S615

页数：2

共 50 条

[41] Uncovering the Gaps: Analyzing Prescribing Patterns of Combination Therapy with SGLT2-inhibitors and GLP-1 Receptor Agonists in Established Atherosclerotic Cardiovascular Disease (ASCVD) and Type 2 Diabetes (T2DM)
Khetrapal, Sanchaya
Gadani, Mrudula
Manalo, Kathryn
Oehler, Andrew
Yin, Yue
Pratapneni, Siddarth
Pulipati, Yochitha
Shah, Aaisha
CIRCULATION, 2024, 150
[42] In Insulin-Naive Patients with T2DM Uncontrolled on GLP-1 Receptor Agonists (GLP-1RA), IDegLira (Novel Combination of Insulin Degludec plus Liraglutide) Resulted in Improved Patient-Reported Outcomes vs. Unchanged GLP-1RA
Linjawi, Sultan
Brod, Meryl
Bode, Bruce W.
Chaykin, Louis B.
Courreges, Jeanpierre
Handelsman, Yehuda
Kongso, Jens Harald
Reiter, PanagIota Diamantopoulou
Simpson, Richard W.
DIABETES, 2015, 64 : A296 - A296
[43] SAFETY AND EFFICACY OF EFRUXIFERMIN IN COMBINATION WITH A GLP-1 RECEPTOR AGONIST (GLP-1RA) IN PATIENTS WITH NASH/MASH AND T2D: A RANDOMIZED, PLACEBO-CONTROLLED STUDY (COHORT D)
Harrison, Stephen A.
Frias, Juan Pablo
Lucas, Kathryn Jean
Reiss, Gary
Neff, Guy W.
Bollepalli, Sureka
Su, Yan
Chan, Doreen
Tillman, Erik
Moulton, Ali
De Temple, Brittany
Zari, Arian
Shringarpure, Reshma
Rolph, Timothy P.
Cheng, Andrew
Yale, Kitty
HEPATOLOGY, 2024, 79 (02) : E76 - E77
[44] Real-World Glycemic Control and Treatment Costs in Patients with T2DM Initiated on Canagliflozin (CANA) 300 mg or a GLP-1
Wysham, Carol H.
Pilon, Dominic
Ingham, Mike
Lafeuille, Marie-Helene
Emond, Bruno
Kamstra, Rhiannon
Pfeifer, Michael
Lefebvre, Patrick
DIABETES, 2017, 66 : A335 - A336
[45] Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM or T2DM
Deeg, Mark
Ilag, Liza
Huster, William J.
Pollom, Robyn K.
Zielonka, Jason
Prince, Melvin J.
Konrad, Robert J.
DIABETES, 2014, 63 : A19 - A19
[46] Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis
Du, Yaping
Bai, Lei
Fan, Bingge
Ding, Haixia
Ding, Haiyan
Hou, Lin
Ma, Hongfang
Xing, Na
Wang, Fujun
PRIMARY CARE DIABETES, 2022, 16 (01) : 156 - 161
[47] Evaluation of Novel Short- and Long-Acting G-protein Biased GLP-1R Agonists for the Treatment of T2DM
Sturchler, Emmanuel
Zhang, Hongkai
Xie, Jia
Dawson, Philip E.
Lerner, Richard A.
Mcdonald, Patricia H.
DIABETES, 2016, 65 : A268 - A268
[48] BAYESIAN NETWORK META-ANALYSIS (NMA) TO ASSESS RELATIVE EFFICACY OF CANAGLIFLOZIN (CANA) VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN DUAL AND TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Van Sanden, S.
Diels, J.
Guillon, P.
Nielsen, A. T.
VALUE IN HEALTH, 2015, 18 (03) : A54 - A54
[49] The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes
Azoulay, Laurent
Simms-Williams, Nikita
Yin, Hui
Lu, Sally
Treves, Nir
Yu, Oriana Hoi Yun
DIABETES, 2023, 72
[50] Comparison of Low-Dose Liraglutide Use Versus Other GLP-1 Receptor Agonists in Patients Without Type 2 Diabetes
Wittbrodt, Eric T.
Eudicone, James M.
Farahbakhshian, Sepehr
McAdam-Marx, Carrie
AMERICAN JOURNAL OF MANAGED CARE, 2018, 24 (08): : S156 - S164

← 1 2 3 4 5 →